

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1-11. (Canceled)

12. (Previously presented) A method of treating a mammal exhibiting a neoplastic disorder comprising the step of administering a therapeutically effective amount of an antibody or antigen binding fragment thereof that binds to IGSF9 or LIV-1, wherein said neoplastic disorder is selected from the group consisting of ovarian cancer, breast cancer, lung cancer, colon cancer, and pancreatic cancer.

13. (Previously presented) The method of claim 12 further comprising the step of administering a therapeutically effective amount of at least one chemotherapeutic agent to said mammal; wherein said chemotherapeutic agent and said antibody or antigen binding fragment thereof may be administered in any order or concurrently.

14. (Previously presented) The method of claim 12, wherein said anti-IGSF9 or anti-LIV-1 antibody or antigen binding fragment thereof is a domain deleted antibody.

15. (Previously presented) The method of claim 14, wherein said domain deleted antibody or antigen binding fragment thereof lacks the CH2 domain.

16. (Previously presented) The method of claim 12, wherein said antibody or antigen binding fragment thereof is humanized.

17. (Previously presented) The method of claim 12, wherein said antibody or antigen binding fragment thereof is associated with a cytotoxic agent.

18. (Previously presented) The method of claim 13, wherein said antibody or antigen binding fragment thereof is administered within two weeks of said chemotherapeutic agent.

19-32. (Canceled)

33. (Previously presented) A method of treating a neoplastic disorder in a mammal wherein neoplastic cells express the IGSF9 or LIV-1 antigens, comprising administering to said mammal a composition comprising a pharmaceutically effective amount of an antibody to IGSF9 or LIV-1, or an antigen binding fragment thereof, wherein said neoplastic disorder is selected from the group consisting of ovarian cancer, breast cancer, lung cancer, colon cancer, and pancreatic cancer.

34-43. (Canceled)